Yuee Teng

2.7k total citations
86 papers, 1.6k citations indexed

About

Yuee Teng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yuee Teng has authored 86 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in Yuee Teng's work include HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (13 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Yuee Teng is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (13 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Yuee Teng collaborates with scholars based in China, United States and Japan. Yuee Teng's co-authors include Xiujuan Qu, Yunpeng Liu, Kezuo Hou, Jingdong Zhang, Ye Zhang, Xiaofang Che, Jinglei Qu, Xuejun Hu, Ling Xu and Lingyun Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Yuee Teng

82 papers receiving 1.6k citations

Peers

Countries citing papers authored by Yuee Teng

Since Specialization

Citations

This map shows the geographic impact of Yuee Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuee Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuee Teng more than expected).

Fields of papers citing papers by Yuee Teng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuee Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuee Teng. The network helps show where Yuee Teng may publish in the future.

Co-authorship network of co-authors of Yuee Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Yuee Teng. A scholar is included among the top collaborators of Yuee Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuee Teng. Yuee Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2) 2025 ·Annals of Oncology ·Erwei Song, Yue Yin, Jiuda Zhao, (unknown), (unknown), Ting Sun, Hang Su, Xiao Tang, Xu Cao, Chi Hao, Xiaofeng Wang, Jin‐Ji Yang, Yuee Teng, Mingyuan Li, Bing Zhao, (unknown), (unknown), Fan Feng	1
2	VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial 2024 ·Annals of Oncology ·Hua Li, Jingyu Liu, Ying Liu, (unknown), Lingling Wang, Zhou Tong, Yuee Teng, Tao Sun, Xiaolin Wang, Jing Cheng, Xin Zhou, (unknown), Minhao Yan, Ji Nie, Carrie Ye, (unknown), Yikai Wang, Xiaohong R. Yang, Eun‐Ji Song	1
3	A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients 2023 ·BMC Cancer ·Shasha Liu, Siyao Du, Gao Si, Yuee Teng, (unknown), Lína Zhang	17
4	Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study) 2023 ·European Journal of Cancer ·Jiayu Wang, Li Cai, Yanqiu Song, Tong Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu	7
5	404P A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer 2023 ·Annals of Oncology ·Jue Wang, Qilong Zhang, Tao Sun, Heng Li, Ying Cheng, Zhongsheng Tong, (unknown), Xinhong Wu, Yuee Teng, Jing Cheng, Zhe‐Sheng Chen, Zhenyu Zhu, Chie‐Schin Shih, Lili Wang, Min Liu, (unknown), Xiaodong Duan, Binghe Xu	0
6	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial 2021 ·BioDrugs ·Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang, (unknown)	28
7	Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence 2020 ·Oncology Research and Treatment ·(unknown), Lu Xu, Jing Shi, Lei Zhao, Sha Shi, Jing Feng, Xu Han, Yu Shi, (unknown), Dongni Wang, (unknown), Xiaoyi Mi, Yuee Teng	6
8	282MO Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial 2020 ·Annals of Oncology ·(unknown), Bin Wang, (unknown), (unknown), Tao Sun, (unknown), Yuee Teng, Min Yan, Xuming Wang, Zefei Jiang, Li Cai, Yueyin Pan	2
9	Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation 2020 ·Frontiers in Oncology ·Yu Shi, Chunlei Zheng, Yue Jin, (unknown), Duo Wang, Kezuo Hou, Jing Feng, (unknown), Xiujuan Qu, Yunpeng Liu, Xiaofang Che, Yuee Teng	97
10	Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance 2020 ·Aging ·Jing Feng, Ti Wen, Zhi Li, (unknown), Lu Zhou, Zichang Yang, Lu Xu, Sha Shi, Kezuo Hou, (unknown), Han Xu, Yuee Teng	34
11	Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer 2020 ·Frontiers in Oncology ·Xin Xing, Ti Wen, (unknown), Mingming Deng, Kezuo Hou, Lu Xu, Sha Shi, Xiujuan Qu, Yunpeng Liu, Xiaofang Che, Yuee Teng	24
12	Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors 2019 ·Pathology - Research and Practice ·Lu Zhou, Zhi Li, (unknown), Bowen Yang, Jing Feng, Lu Xu, Yuee Teng	4
13	Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab 2018 ·Annals of Oncology ·(unknown), Binghe Xu, (unknown), Tao Sun, (unknown), Yuee Teng, Xin Hu, Igor Bondarenko, Hryhoriy Adamchuk, (unknown), Dmytro Trukhin, (unknown), Hong Zheng, Zhongsheng Tong, (unknown), (unknown), Wenlei Jiang, Shuyu Liu, Andrea O. Y. Luk	4
14	Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report 2018 ·BMC Cancer ·Bo Jin, Simeng Zhang, (unknown), Ping Yu, Ying Chen, Yuee Teng, Xiaofang Che, Yibo Fan, Chunlei Zheng, Xiaohan Li, Xueshan Qiu, Xiujuan Qu, Yunpeng Liu	7
15	A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy 2016 ·Translational Oncology ·Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jingdong Zhang, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu	17
16	C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway 2011 ·Oncology Letters ·Lingyun Zhang, Yuee Teng, Ye Zhang, Jing Liu, Ling Xu, Jinglei Qu, Kezuo Hou, Xianghong Yang, Yunpeng Liu, Xiujuan Qu	44
17	Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer 2010 ·BMC Cancer ·(unknown), Yuee Teng, Bo Jin, Mingfang Zhao, Ping Yu, Xuejun Hu, Jingdong Zhang, Songbai Li, (unknown), Yunpeng Liu	21
18	The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells 2009 ·Acta Oncologica ·Jinglei Qu, Xiujuan Qu, Mingfang Zhao, Yuee Teng, Ye Zhang, Kezuo Hou, Youhong Jiang, Xianghong Yang, Yunpeng Liu	40
19	PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells 2008 ·Anti-Cancer Drugs ·Dan Li, Xiujuan Qu, Kezuo Hou, Ye Zhang, Qian Dong, Yuee Teng, Jingdong Zhang, Yunpeng Liu	141
20	Immunohistochemical localization of Leu‐M₁ carbohydrate antigen in human oral squamous cell carcinoma 1989 ·Journal of Oral Pathology and Medicine ·Yuee Teng, (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact